https://scholars.lib.ntu.edu.tw/handle/123456789/514557
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Liu C.-S. | en_US |
dc.contributor.author | Shen Y.-Y. | en_US |
dc.contributor.author | Lin C.-C. | en_US |
dc.contributor.author | RUOH-FANG YEN | en_US |
dc.contributor.author | Kao C.-H. | en_US |
dc.creator | Liu C.-S.;Shen Y.-Y.;Lin C.-C.;Ruoh-Fang Yen;Kao C.-H. | - |
dc.date.accessioned | 2020-09-23T06:22:49Z | - |
dc.date.available | 2020-09-23T06:22:49Z | - |
dc.date.issued | 2002 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/514557 | - |
dc.description.abstract | Objective: To evaluate retrospectively the impact of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) on the detection of recurrent breast cancer based on asymptomatically elevated tumor markers levels. Methods: Whole-body FDG-PET was performed in 30 patients with suspected recurrent breast cancer and asymptomatic tumor marker increase but negative or equivocal other imaging modality results. A blood sample was drawn in each case for marker assay (CA 15-3 and CEA) on the same day as the FDG-PET. All of these 30 asymptomatic patients had either CA l5-3 >32 U/ml or CEA >5 ng/ml. The final diagnosis of recurrent breast cancer was established by operation/biopsy histopathological findings or clinical follow-up for >1 year by additional morphological imaging techniques. Results: Among the 30 patients, the final diagnosis of recurrent breast cancer was established in 38 sites in 28 patients. FDG-PET accurately detected 35/38 sites in 25/28 patients with recurrence. The diagnostic sensitivity and accuracy of FDG-PET in patients with suspected recurrent breast cancer and asymptomatically elevated tumor markers were 96 and 90%, respectively. Conclusions: FDG-PET is a useful technique for detecting recurrent breast cancer suspected from asymptomatically elevated tumor markers levels and has an important clinical impact on the management of these patients. ? 2002 Foundation for Promotion of Cancer Research. | - |
dc.relation.ispartof | Japanese Journal of Clinical Oncology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | CA 15-3 antigen; carcinoembryonic antigen; fluorodeoxyglucose f 18; medronate technetium tc 99m; tumor marker; diagnostic agent; fluorodeoxyglucose f 18; tumor marker; adult; article; blood sampling; breast cancer; breast surgery; cancer localization; clinical article; controlled study; diagnostic accuracy; diagnostic imaging; female; follow up; histopathology; human; human tissue; morphometrics; patient care; positron emission tomography; protein blotting; recurrent cancer; sensitivity analysis; whole body tomography; aged; breast tumor; computer assisted emission tomography; evaluation; middle aged; retrospective study; tumor recurrence; Adult; Aged; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Tomography, Emission-Computed; Tumor Markers, Biological | - |
dc.title | Clinical impact of [18F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: A preliminary report | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1093/jjco/hyf052 | - |
dc.identifier.pmid | 12324574 | - |
dc.identifier.scopus | 2-s2.0-0036652329 | - |
dc.relation.pages | 244-247 | - |
dc.relation.journalvolume | 32 | - |
dc.relation.journalissue | 7 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Radiology | - |
crisitem.author.dept | Nuclear Medicine-NTUH | - |
crisitem.author.orcid | 0000-0003-1648-6482 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。